DCprime

OSLO: PCI  Biotech has  announced an  extensive research collaboration. Within the  collaboration,  DCprime  and  PCI  Biotech  will combine their know-how and technology  platforms  to  pursue  the  development  of novel cancer vaccination concepts based on tumour-independent antigens (TIAs). PCI  Biotech  is  a  biopharmaceutical  late  stage clinical development company focusing  on  development  and  commercialisation  of  novel …